2024
Open and Endovascular Treatment of the Common Femoral Artery in a Tertiary Care Center
Wells N, Hundito A, Tuttle M, Alameddine D, Aboian E, Arhuidese I, Fischer U, Perez-Lozada J, Guzman R, Ochoa Chaar C. Open and Endovascular Treatment of the Common Femoral Artery in a Tertiary Care Center. Journal Of Vascular Surgery 2024 PMID: 39442735, DOI: 10.1016/j.jvs.2024.10.027.Peer-Reviewed Original ResearchLower extremity revascularizationTreated with open surgeryPeripheral arterial diseaseCFA endarterectomyEndovascular therapyOpen surgeryEndovascular treatmentEndovascular lower extremity revascularizationTreated with endovascular therapyCompared to open surgeryAssociated with higher perioperative complicationsLower extremity revascularization proceduresPost-operative bleedingFemoral arteryImprove patient selectionKaplan-Meier analysisTertiary care centerTertiary-care centerLong-term outcomesEndovascular treatment of peripheral arterial diseaseLonger hospital lengthMALE-free survivalMultivariate logistic regressionTreatment of peripheral arterial diseaseCommon femoral artery
2021
Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group